Goldman Sachs
ABEO icon

Goldman Sachs’s Abeona Therapeutics ABEO Stock Holding History

Goldman Sachs’s Portfolio ABEO Stock Details ABEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-1,516
Closed -$544K – 5618
2018
Q1 		$544K Buy
+1,516
New +$563K ﹤0.01% 4436

Other funds holding ABEO

NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
CCC
Cable Car Capital San Francisco, California $289M AUM 26.33% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
PBM
Propel Bio Management Los Angeles, California $159M AUM 60.94% 1-Year Est. Return
KCM
Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Goldman Sachs's ABEO Position: Q1 2026 in Review

Goldman Sachs increased its Abeona Therapeutics (ABEO) stake by 125% in Q1 2026, buying an estimated $3.14M and bringing the position to 1,130,619 shares worth $5.07M. The position accounts for ﹤0.01% of the portfolio, ranked #3679.

Goldman Sachs first reported a position in ABEO in Q4 2015 and has held it in 34 quarters since. 108 funds tracked by Wall St. Rank hold ABEO as of Q1 2026.

  • Goldman Sachs held 1,130,619 shares of Abeona Therapeutics worth $5.07M as of Q1 2026.
  • Goldman Sachs bought 628,435 Abeona Therapeutics shares in Q1 2026, an estimated $3.14M.
  • Abeona Therapeutics made up ﹤0.01% of Goldman Sachs's portfolio in Q1 2026, its #3679 holding.
  • Goldman Sachs first reported a position in Abeona Therapeutics in Q4 2015 and has held it in 34 quarters since.
  • 108 funds tracked by Wall St. Rank held Abeona Therapeutics as of Q1 2026.

Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.